CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Association of diltiazem and niclosamideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug956 high flow nasal cannula (HFNC) Wiki 1.00
drug657 Prone positioning (PP) Wiki 1.00
drug776 Standard of care (SOC) Wiki 1.00
drug360 Hydroxychloroquine Wiki 0.13

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.16
D012127 Respiratory Distress Syndrome, Newborn NIH 0.15
D012128 Respiratory Distress Syndrome, Adult NIH 0.13
D014777 Virus Diseases NIH 0.11
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial

No optimal antiviral intervention has been yet validated to treat COVID-19 disease. Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are associated with poor prognosis. This study aims to evaluate the efficacy of two experimental antiviral treatments, compared to standard of care (SOC), to prevent clinical worsening, hospitalization or death at day 14 in adults with documented SARS-CoV-2 infection, asymptomatic or with symptoms lasting less than 8 days, and associated comorbidities without any severity criteria of the disease at inclusion. Participants will be randomized to receive SOC alone or SOC + hydroxychloroquine 200 mg three times a day during 10 days or SOC + association of niclosamide 2 g at J1 then 500 mg two times a day with diltiazem 60 mg three times a day during 10 days. Efficacy and tolerance of each treatments will be compared across the three treatment groups during the 28 days of follow-up.

NCT04372082 Sars-CoV2 Other: Standard of care (SOC) Drug: Hydroxychloroquine Drug: Association of diltiazem and niclosamide

Primary Outcomes

Description: Composite criteria

Measure: death

Time: At day 14

Description: clinical worsening defined by at least one of the NEWS score item > 2 (temperature >39,1°C or<35°C, cardiac rate >111 or ≤40 bpm, respiratory rate > 21 or ≤8 cycles par minute, SaO2 ≤ 93% room air (if its measure is available),need of oxygen

Measure: clinical worsening (composite criteria)

Time: At day 14

Measure: Assisted-ventilation and/or hospitalization (composite criteria)

Time: At day 14

Secondary Outcomes

Description: clinical state as reflected by NEWS scoring, the clinical state of the patient regarding respiratory state as defined by the NEWS scoring system

Measure: National Early Warning Score (NEWS)

Time: at day 3, day 8, day 14 day 28

Measure: cumulative incidence of hospitalizations

Time: at day 14

Measure: cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)

Time: at day 14

Description: Number of patients death

Measure: Mortality

Time: at day 14 and at day 28

Measure: cumulative incidence of viral shedding on SARS-CoV-2 rt-PCR on nasopharyngeal swab;

Time: at day 3, day 8

Measure: adverse drug reactions

Time: during study, up to 28 days

No related HPO nodes (Using clinical trials)